Date: November 16, 2026
To,
The Department of Corporate Services,
BSE Limited, Mumbai
BSE Script Code : 540359

Dear Sir,

SUB: OUTCOME OF BOARD MEETING HELD ON NOVEMBER 16, 2026 AND SUBMISSION OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 WITH LIMITED REVIEW REPORT PURSUANT TO THE PROVISIONS OF REGULATIONS 30 AND 33 (READ WITH PART A OF SCHEDULE III) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

With reference to the above subject, we would like to inform you that the Board of Directors of Parmax Pharma Limited (the Company') at its adjourned meeting held today i.e. Monday, November 16, 2026 inter-alia The Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026, along with the Limited Review Report issued by the Statutory Auditors of the Company thereon.

A copy of the aforesaid Unaudited Financial Results together with the Limited Review Report is enclosed herewith as Annexure – A

The meeting of Board of Directors commenced at 17:30 IST and ended at 18:00 IST.

Thanking you.

Yours faithfully,
Parmax Pharma Limited,

UMANG ALKESH GOSALIA
Digitally signed by UMANG ALKESH GOSALIA
Date: 2026.11.16 19:24:57 +05'30'

Umang Gosalia
Managing Director
DIN: 05153830

Statement of Standalone Unaudited Results for the Quarter & Half year ended 30.09.2026

(In Rs. Thousands)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	117042.53	82209.52	25308.70	199252.05	44731.81	121115.93
II.	Other income	22480.56	20791.30	70.16	43271.86	137.01	468.06
III.	**Total Income (I+II)**	**139523.09**	**103000.81**	**25378.86**	**242523.91**	**44868.83**	**121583.99**
IV.	**Expenses**						
	(a) Cost of materials consumed	91368.99	50389.23	26780.68	141758.22	35277.49	130633.91
	(b) Purchase of stock-in-trade	0.00	0	0.00	0.00	0.00	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	22508.36	6851.24	-1225.88	29359.59	0.51	-31800.34
	(d) Employee benefits expense	8291.20	6417.39	6594.57	14708.60	12909.69	25049.355
	(e) Finance Costs	2262.38	2290.62	2400.04	4553.00	5201.06	12399.56
	(f) Depreciation and amortisation expense	4915.66	4792.02	2558.02	9707.68	4970.44	10135.0157
	(g) Other expenses	8446.89	10265.40	9055.09	18712.29	14938.28	33623.79
	Total expenses (IV)	**137793.49**	**81005.89**	**46162.52**	**218799.38**	**73297.46**	**180041.29**
V	**Profit/(Loss) from operations before exceptional items and tax (I-IV)**	1729.61	21994.93	-20783.66	23724.53	-28428.63	-58457.30
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0
VII	**Profit/ (Loss) before tax (V-VI)**	**1729.61**	**21994.93**	**-20783.66**	**23724.53**	**-28428.63**	**-58457.30**
VIII	Tax expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	0
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	-16866.49
IX	**Net Profit / (Loss) for the period from continuing operations (VII-VIII)**	1729.61	21994.93	-20783.66	23724.53	**-28428.63**	**-41590.82**
X	**Profit/(loss) from discontinued operations**						
XI	Tax expense of discontined operations	0.00	0.00	0.00	0.00	0.00	0
XII	**Profit/(loss) from Discontined operations (after tax) (X-XI)**	0.00		0.00	0.00	0.00	0
XIII	**Profit (Loss) for the period (IX+XII)**	**1729.61**	**21994.93**	**-20783.66**	**23724.53**	**-28428.63**	**-41590.82**
XIV	Other Comprehensive Income A. (i) Items that will not be reclassifled to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B. (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0
XV	**Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)**	**1729.61**	**21994.93**	**-20783.66**	**23724.53**	**-28428.63**	**-41590.82**
XVI	**Paid-up equity share capital (Face Value Rs 10)**	68788.86	37413.00	37413.00	68788.86	37413.00	37413000
XVII	**Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):** (a) Basic (In Rs) (b) Diluted	0.25	5.88	-5.56	3.45	-7.60	-11.12

Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 16th November, 2026

2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and half year ended 30th September, 2026

3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.

4. Statement of Unaudited Financial Results of the company for the Quarter and half year ended 30th September, 2026 in the prescribed format under Schedule III of Companies Act, 2013

5. The figures for the previous period have been regrouped wherever necessary.

6. During the half year ended 30th September, 2026, Company has not charged the depreciation on the clean room plant and effluent treatment plant and figures of depreciation for the quarter and half year ended herein above is excluding of depreciation on clean room plant and effluent treatment plant.

7. The fire incident took place at the manufacturing facility of the Company on 28.09.2026 and Plant Machinery, Finished, Semi- finished Material was damaged. The management is in the process of ascertaining the amount of loss due to this fire incident, hence no effect is given in the Financial statements of quarter and half year ended 30.09.2026.

8. Based on the representations and confirmation received from the Creditors of Company, Company has written-Back its debt of Rs.2.32 Crores and it is forming part of other Income.

9. The Board of Directors at their meeting held on 29-08-2026 approved the allotment of 31,37,586 equity shares of Rs. 10/- at Rs. 36.50/- and alloted 21,45,145 convertible warrants at Rs. 36.50/- (Paid-up Rs.9.125).

FOR, PARMAX PHARMA LIMITED

UMANG ALKESH GOSALIA

Digitally signed by UMANG ALKESH GOSALIA
Date: 2026.11.16 19:18:11 +05'30'

Place: Mumbai
Date: 16.11.2026

Umang Gosalia
Managing Director

Mfg. of : Bulk Drugs, Drug Intermediates & Speciality Chemicals

PARMAX PHARMA LTD.

STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2026

(In Rs. Thousands)

Sr. No.	Particulars	As at 30.09.2026 (Unaudited)	As at 31.03.2026 (Audited)
I.	**Assets**		
1	**Non-current assets**		
	(a) Property, Plant and Equipment	109068.52	78598.58
	(b) Capital work-in-progress	0.00	0.00
	(c) Investment Property	0.00	0.00
	(d) Goodwill	0.00	0.00
	(e) Other Intangible assets	0.00	0.00
	(f) Intangible assets under development	180.00	0.00
	(g) Biological Assets other than bearer plants	0.00	0.00
	(h) Financial Assets	0.00	0.00
	(i) Investments	4006.00	4006.00
	(ii) Trade receivables	0.00	0.00
	(iii) Loans	0.00	12334.60
	(i) Deferred tax assets (net)	18810.80	18810.80
	(j) Other non-current assets		0.00
	Total Non-Current Assets	**132065.32**	**113749.98**
2	**Current assets**		
	(a) Inventories	48121.59	78493.26
	(b) Financial Assets	0.00	0.00
	(i) Investments	0.00	0.00
	(ii) Trade receivables	115073.12	31627.59
	(iii) Cash and cash equivalents	70856.79	6496.84
	(iv) Bank balances other than(iii) above	0.00	0.00
	(v) Loans	10777.23	50165.14
	(vi) Others (to be specified)	0.00	0.00
	(c) Current Tax Assets (Net)	0.00	0.00
	(d) Other current assets	3639.02	0.00
	Tatal Current Assets	**248467.75**	**166782.83**
	Total Assets	**380533.97**	**280532.81**
II.	**EQUITY AND LIABILITIES**		
1	Equity		
	(a) Equity Share capital	81250.22	44511.50
	(b) Other Equity	12426.23	-105989.02
	Total Equity	**93676.45**	**-61477.52**
2	**LIABILITIES**		
i.	Non-current liabilities	0.00	
	(a) Financial Liabilities	0.00	0.00
	(i) Borrowings	110283.82	115182.41
	(ii) Trade payables	0.00	0.00
	(iii)Other financial liabilities (other than those specified in item (b), to be specified	0.00	0.00
	(b) Provisions	0.00	0.00
	(c) Deferred tax liabilities (Net)	0.00	0.00
	(d) Other non-current liabilities	0.00	0.00
	Total of Non-Current Liabilities	**203960.27**	**115182.41**
ii.	Current liabilities		
	(a) Financial Liabilities	0.00	0.00
	(i) Borrowings	0.00	0.00
	(ii) Trade payables	169017.12	143437.94
	(iii) Other financial liabilities (other than those specified in item (c)	0.00	0
	(b) Other current liabilities	5104.90	78671.69
	(c) Provisions	2451.43	4718.29
	(d) Current Tax Liabilities (Net)	0.00	0.00
			0.00
	Total of Current Liabilities	**176573.45**	**226827.92**
	Total Equity and Liabilities	**380533.97**	**280532.81**

FOR, PARMAX PHARMA LIMITED

UMANG ALKESH GOSALIA

Digitally signed by UMANG ALKESH GOSALIA
Date: 2026.11.16 19:18:51 +05'30'

Place: Mumbai
Date: 16.11.2026

Umang Gosalia
Managing Director

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. **Tel.:** Fac.+91-2827-270534 - 35 **Fax :** +91-2827-270536 **e-mail :** info@parmaxpharma.com **CIN :** L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot – 360 004, Gujarat (INDIA)

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2026					
					(Amt. Rs. Thousands)
	PARTICULARS		Half Year Period Ended on 30/09/2026	Half Year Period Ended on 30/09/2025	Period Ended on 31/03/2026
			Unaudited	Unaudited	Audited
(A)	**CASH FLOW FROM OPERATING ACTIVITIES**				
	Net Profit After Extraordinary Item but Before Taxation:		**23724.53**	**-28428.64**	**-41590.82**
	Adjustments for:				
	Depreciation		9707.68	4970.43	10135.02
	Provision for Current Tax		0.00	0.00	0.00
	Current tax expenses relating to prior year		0.00	0.00	0.00
	Provision for Deferred Tax Assets		0.00	0.00	-16866.49
	Loss on account of damaged assets				0
	Operating profit before Working Capital changes		**33432.21**	**-23458.21**	**-48322.29**
	Adjustments for changes in Working Capital:				
	(Increase) / Decrease in Inventories		30371.7	2290.4	-45349.60
	(Increase) / Decrease in Trade & Other Receivables		-83445.5	12364.3	-18865.02
	(Increase) / Decrease in Short term Loans and Advances		35748.9	-2755.6	-7570.45
	Increase / (Decrease) in Current Liabilities		-50254.5	-21257.7	97596.22
	Increase / (Decrease) in Tax Provisions		0.0	0.0	-1143.15
	(Increase) / Decrease in Non Current Assets		0.0	-534.4	0.00
	(Increase) / Decrease in Long term Loans & Advances		-12334.6	0.0	100.00
	Cash generated from Operations		-79914.0	-9893.0	24768.01
	Net Cash from Operating activities	(A)	**-46481.83**	**-33351.17**	**-23554.28**
(B)	**CASH FLOW FROM INVESTING ACTIVITIES**				
	Purchase of Fixed Assets		-39413.6	-4561.5	-8999.0
	Net Cash from / (Used in) Investing activities	(B)	**-39413.60**	**-4561.47**	**-8998.96**
(C)	**CASH FLOW FROM FINANCING ACTIVITIES**				
	Increase / (Decrease) in other Long Term Borrowings		-4898.60	38060.08	38146.80
	(Increase)/ Decrease in Non Current Investment		0.00	0.00	0.00
	Increase/ (Decrease) in Equity Share Capital		36738.72	0.00	0.00
	Increase/ (Decrease) in Other Equity		118415.25	0.00	0.00
	Net Cash (Used in) Financing activities	(C)	**150255.38**	**38060.08**	**38146.80**
	Net Increase in Cash & Cash Equivalents (A + B + C)		**64359.95**	**147.44**	**5593.56**
	Cash & Cash Equivalents at the beginning of the year		**6496.84**	**903.27**	**903.28**
	Cash & Cash Equivalents at the end of the year		**70856.79**	**1050.71**	**6496.84**

FOR, PARMAX PHARMA LIMITED

UMANG ALKESH GOSALIA

Digitally signed by UMANG ALKESH GOSALIA
Date: 2026.11.16 19:19:10 +05'30'

Place: Mumbai
Date: 16.11.2026

Umang Gosalia
Managing Director

B A SHAH S R MEHTA & Co.
Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors,

PARMAX PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **PARMAX PHARMA LIMITED** ("the Company") for the quarter and half year ended 30th September, 2026, together with the Unaudited Standalone Statement of Assets and Liabilities as at 30th September, 2026 and the Unaudited Standalone Statement of Cash Flows for the half year ended on that date ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors at its meeting held on 14th November, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, *"Interim Financial Reporting"* ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company

Head Office:
209-Sapphire Complex, II[nd] Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:
(O) 0281-2468261
(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

5. We draw attention to the following notes to the accompanying Statement:
a) **Note No.8** to the Statement, regarding the write-back of long-outstanding related party balances aggregating to ₹ 2.24 Crore (₹ 2,23,66,683), comprising ₹ 1.87 Crore payable towards capital goods and ₹ 0.07 Crore towards loan from Malwin Pharma Pvt. Ltd., and ₹ 0.29 Crore towards unsecured loan from Director Mr. Umang A. Gosalia, credited to Other Income (Exceptional Item) during the quarter ended 30th September, 2026 pursuant to written waivers and approvals of the Audit Committee and the Board of Directors.

b) **Note No 7** to the Statement, regarding a fire accident on 28th September, 2026 at the Company's factory premises at Hadamtala, Dist. Rajkot, causing damage to Property, Plant and Equipment and inventories with a management-estimated Rs 6 Crore and Whereas intimation to Insurance Co. Amounting to Rs 4.75 Crore. Pending completion of the loss survey and acceptance of the claim by the Insurance Company, no insurance claim receivable has been recognised in the Statement in accordance with Ind AS 37.

B A SHAH S R MEHTA & Co.
Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

c) **Note No 6** to the Statement, regarding non-provision of depreciation on the Company's Effluent Treatment Plant (ETP) during the quarter ended 30th September, 2026 on account of non-usage of the asset during the period, and management's assessment of its useful life, residual value, and recoverability.

Our conclusion on the Statement is not modified in respect of the above matters.

For **B. A. SHAH S R MEHTA & Co.**
Chartered Accountants
FRN NO: 128796W

Place: Rajkot
Date: 16.11.2026

B A SHAH S R MEHTA & CO. RAJKOT Chartered Accountants

MALAY B SHAH
Partner
M. No. 159526
UDIN: 26159526UPEYYP2520

Head Office:
209-Sapphire Complex, II[nd] Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:
(O) 0281-2468261
(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com